文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于左氧氟沙星和克拉霉素的铋剂四联疗法根除幽门螺杆菌的疗效比较

The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Eradication.

作者信息

Arj Abbas, Mollaei Marzieh, Razavizadeh Mohsen, Moraveji Alireza

机构信息

Authoimmune Disease Research Center, Kashan University of Medical Sciences, Kashan, Iran.

出版信息

J Res Pharm Pract. 2020 Jun 26;9(2):101-105. doi: 10.4103/jrpp.JRPP_19_86. eCollection 2020 Apr-Jun.


DOI:10.4103/jrpp.JRPP_19_86
PMID:33102384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7547743/
Abstract

OBJECTIVE: The aim of the current study was to compare the efficacy of quadruple therapy including levofloxacin and clarithromycin for eradication. METHODS: This clinical trial study was conducted on 189 patients with infection who underwent gastroscopy and stomach biopsy in Shahid Beheshti Hospital, Kashan, Iran. After classification of patients, one group was treated with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12 h), amoxicillin (1 g/12 h), and clarithromycin (500 mg/12 h) and other group with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12h), amoxicillin (1 g/12 h), and levofloxacin (500 mg/12 h) for 2 weeks. After the end of the antibiotic treatment, omeprazole therapy was continued for 4 weeks. Two weeks after discontinuation of omeprazole, fecal antigen test was performed for both the groups to confirm the eradication of infection. FINDINGS: The success of eradication in the levofloxacin and clarithromycin groups was observed in 78 (89.7%) and 71 (69.6%) patients, respectively ( < 0.01). A significant difference was also seen between the two groups in terms of side effects and its incidence ( < 0.01), so that the incidence of side effect types in the clarithromycin group was more than the levofloxacin group except muscular pain and fatigue ( < 0.01). CONCLUSION: Levofloxacin-based quadruple regimen therapy was superior to clarithromycin-based quadruple regimens regarding eradication and side effects. Therefore, the levofloxacin-based regimen can be considered as an effective treatment for the first-line anti- therapy.

摘要

目的:本研究旨在比较含左氧氟沙星和克拉霉素的四联疗法根除幽门螺杆菌的疗效。 方法:本临床试验研究对189例幽门螺杆菌感染患者进行,这些患者在伊朗卡尚的沙希德·贝赫什提医院接受了胃镜检查和胃活检。患者分类后,一组接受枸橼酸铋钾(120毫克,2片/12小时)、奥美拉唑(20毫克/12小时)、阿莫西林(1克/12小时)和克拉霉素(500毫克/12小时)治疗,另一组接受枸橼酸铋钾(120毫克,2片/12小时)、奥美拉唑(20毫克/12小时)、阿莫西林(1克/12小时)和左氧氟沙星(500毫克/12小时)治疗,疗程均为2周。抗生素治疗结束后,奥美拉唑治疗继续4周。奥美拉唑停药2周后,对两组患者进行粪便抗原检测以确认幽门螺杆菌感染是否根除。 结果:左氧氟沙星组和克拉霉素组分别有78例(89.7%)和71例(69.6%)患者幽门螺杆菌根除成功(P<0.01)。两组在副作用及其发生率方面也存在显著差异(P<0.01),除肌肉疼痛和疲劳外,克拉霉素组副作用类型的发生率高于左氧氟沙星组(P<0.01)。 结论:在幽门螺杆菌根除和副作用方面,基于左氧氟沙星的四联疗法优于基于克拉霉素的四联疗法。因此,基于左氧氟沙星的方案可被视为一线抗幽门螺杆菌治疗的有效方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3230/7547743/4456b4994bae/JRPP-9-101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3230/7547743/4456b4994bae/JRPP-9-101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3230/7547743/4456b4994bae/JRPP-9-101-g001.jpg

相似文献

[1]
The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Eradication.

J Res Pharm Pract. 2020-6-26

[2]
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.

Lancet Gastroenterol Hepatol. 2023-3

[3]
High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.

Asian Pac J Cancer Prev. 2015

[4]
Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of H. Pylori Infection.

Acta Medica (Hradec Kralove). 2020

[5]
Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication.

World J Gastroenterol. 2010-9-14

[6]
Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.

Scand J Gastroenterol. 2013-6

[7]
A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial.

Clin Gastroenterol Hepatol. 2004-11

[8]
A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection.

Helicobacter. 2010-4

[9]
Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.

Clin Res Hepatol Gastroenterol. 2023-1

[10]
Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Dig Dis Sci. 2013-10-15

引用本文的文献

[1]
An Update on Eradication of in Iran: A Review.

Middle East J Dig Dis. 2024-7

[2]
Unravelling Peptic Ulcers: Comprehensive Insights into Etiology, Diagnosis, Screening Techniques, and Treatment.

Curr Pharm Des. 2025

本文引用的文献

[1]
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions.

Gastroenterology. 2018-7-7

[2]
Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.

Sci Rep. 2018-6-13

[3]
Eradication of in Iran: A Review.

Middle East J Dig Dis. 2018-1

[4]
Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of infection in Syrian population single-center experience.

Avicenna J Med. 2018

[5]
Comparison of levofloxacin versus clarithromycin efficacy in the eradication of Helicobacter pylori infection.

Caspian J Intern Med. 2016

[6]
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

Gut. 2016-10-5

[7]
Meta-analysis of the Prevalence of Helicobacter Pylori Infection among Children and Adults of Iran.

Int J Prev Med. 2016-3-1

[8]
Helicobacter pylori and functional dyspepsia: an unsolved issue?

World J Gastroenterol. 2014-7-21

[9]
Helicobacter pylori: management in 2013.

World J Gastroenterol. 2014-5-14

[10]
Treatment of Helicobacter pylori infection: current status and future concepts.

World J Gastroenterol. 2014-5-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索